{"disease":{"id":"ent-tumor","name":"ent tumor"},"drugs":{"marketed":[{"drug_id":"osimertinib","indication_name":"First-line treatment of adult patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tagrisso","generic_name":"osimertinib","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"ALK tyrosine kinase receptor","drug_class":"Kinase Inhibitor [EPC]","quality_score":67,"revenue":"5800","mechanism":"Osimertinib is a kinase inhibitor of the epidermal growth factor receptor (EGFR) that binds irreversibly to mutant forms of EGFR."},{"drug_id":"osimertinib","indication_name":"First-line treatment of adult patients with locally advanced or metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, in combination with pemetrexed and platinum-based chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tagrisso","generic_name":"osimertinib","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"ALK tyrosine kinase receptor","drug_class":"Kinase Inhibitor [EPC]","quality_score":67,"revenue":"5800","mechanism":"Osimertinib is a kinase inhibitor of the epidermal growth factor receptor (EGFR) that binds irreversibly to mutant forms of EGFR."},{"drug_id":"osimertinib","indication_name":"Adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tagrisso","generic_name":"osimertinib","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"ALK tyrosine kinase receptor","drug_class":"Kinase Inhibitor [EPC]","quality_score":67,"revenue":"5800","mechanism":"Osimertinib is a kinase inhibitor of the epidermal growth factor receptor (EGFR) that binds irreversibly to mutant forms of EGFR."},{"drug_id":"osimertinib","indication_name":"Treatment of adult patients with locally advanced, unresectable (stage III) NSCLC whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tagrisso","generic_name":"osimertinib","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"ALK tyrosine kinase receptor","drug_class":"Kinase Inhibitor [EPC]","quality_score":67,"revenue":"5800","mechanism":"Osimertinib is a kinase inhibitor of the epidermal growth factor receptor (EGFR) that binds irreversibly to mutant forms of EGFR."},{"drug_id":"nivestym","indication_name":"Enhancement of an antitumor effect of dinutuximab for neuroblastoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Neupogen","generic_name":"Filgrastim-Aafi","company_name":"Amgen","drug_phase":"marketed","molecular_target":"G-CSF receptor (granulocyte colony-stimulating factor receptor)","drug_class":"Colony-stimulating factor (CSF); leukocyte growth factor","quality_score":10,"revenue":"1434.0","mechanism":"Filgrastim-aafi binds G-CSF receptors on hematopoietic cells, stimulating neutrophil proliferation, differentiation, and functional activation."},{"drug_id":"cyclophosphamide","indication_name":"Treatment prior to tumor-specific T-cell infusion therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytoxan (Lyophilized)","generic_name":"cyclophosphamide","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Tumor cell DNA","drug_class":"Alkylating agent","quality_score":10,"revenue":"1000.0","mechanism":"Cyclophosphamide cross-links tumor cell DNA and interferes with malignant cell growth through active alkylating metabolites."},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-negative tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor and with a HER2-low tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"cyclophosphamid","indication_name":"Treatment prior to tumor-specific T-cell infusion therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cyclophosphamid","company_name":"Zhejiang University","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"bcg","indication_name":"Treatment of non-muscle invasive bladder cancer (NMIBC) with high-grade tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of non-muscle invasive bladder cancer (NMIBC) with high-risk tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC))","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chembl-chembl1200796","indication_name":"Treatment prior to tumor-specific T-cell infusion therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytoxan (Lyophilized)","generic_name":"CYCLOPHOSPHAMIDE","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"cyclophosphamide","quality_score":10,"revenue":null,"mechanism":"Cytoxan works by interfering with the DNA replication process in rapidly dividing cancer cells."},{"drug_id":"bendamustin","indication_name":"Treatment prior to tumor-specific T-cell infusion therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Bendamustin","company_name":"Meir Medical Center","drug_phase":"marketed","molecular_target":"Histone deacetylase 1, Histone deacetylase 10, Histone deacetylase 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"dostarlimab-gxly","indication_name":"Mismatch Repair Deficient Recurrent or Advanced Solid Tumors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"JEMPERLI","generic_name":"DOSTARLIMAB-GXLY","company_name":"GLAXOSMITHKLINE","drug_phase":"marketed","molecular_target":"PD-1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":"Dostarlimab-gxly blocks PD-1 receptor interaction with PD-L1 and PD-L2, enhancing anti-tumor immune response."},{"drug_id":"etoposid","indication_name":"Treatment prior to tumor-specific T-cell infusion therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Etoposid","company_name":"University of Ulm","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, Canalicular multispecific organic anion transporter 2, Multidrug resistance-associated protein 6","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"bacillus-calmette-guerin","indication_name":"Prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection (TUR)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bacillus-calmette-guerin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Mycobacterium tuberculosis","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"neupogen","indication_name":"Enhancement of an antitumor effect of dinutuximab for neuroblastoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Neupogen","company_name":"University of Chicago","drug_phase":"marketed","molecular_target":"Granulocyte colony-stimulating factor receptor","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"etoposide","indication_name":"Treatment prior to tumor-specific T-cell infusion therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vepesid","generic_name":"etoposide","company_name":"Bristol-Myers Squibb K.K.","drug_phase":"marketed","molecular_target":"DNA topoisomerase 2-alpha","drug_class":"Topoisomerase Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"larotrectinib","indication_name":"NTRK fusion gene-positive advanced or recurrent solid tumors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vitrakvi","generic_name":"LAROTRECTINIB","company_name":"Bayer","drug_phase":"marketed","molecular_target":"High affinity nerve growth factor receptor","drug_class":"Kinase Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Vitrakvi works by blocking the activity of a specific protein called the nerve growth factor receptor."},{"drug_id":"bendamustine","indication_name":"Treatment prior to tumor-specific T-cell infusion therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Treanda","generic_name":"BENDAMUSTINE","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Histone deacetylase 6","drug_class":"Alkylating Drug","quality_score":63,"revenue":null,"mechanism":"Treanda works by attaching an alkyl group to the DNA of cancer cells, interfering with their ability to replicate and grow."}],"pipeline":[],"offLabel":[],"totalMarketed":101,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05793281","title":"An Observational Study to Learn More About NTRK Gene Fusion Positive in Solid Tumor in Japan","phase":"","overall_status":"COMPLETED","enrollment_count":46621,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT03840928","title":"PatientSpot Formerly Known as ArthritisPower","phase":"","overall_status":"UNKNOWN","enrollment_count":40000,"lead_sponsor_name":"Global Healthy Living Foundation","has_results":false},{"nct_id":"NCT00898365","title":"Study of Kidney Tumors in Younger Patients","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":8000,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT00736749","title":"Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT04351035","title":"National Wide Cross-sectional Study in Paediatric Central Nervous System Tumours in China -- the CNOG-MC001 Registry","phase":"","overall_status":"COMPLETED","enrollment_count":4303,"lead_sponsor_name":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT04282083","title":"Protocol ITANET - Registry","phase":"","overall_status":"RECRUITING","enrollment_count":3600,"lead_sponsor_name":"Italian Association Neuroendocrine Tumors","has_results":false},{"nct_id":"NCT05534178","title":"Machine Learning Model to Predict HOLS and Mortality After Discharge in Hospitalized Oncologic Patients","phase":"","overall_status":"UNKNOWN","enrollment_count":2500,"lead_sponsor_name":"Vall d'Hebron Institute of Oncology","has_results":false},{"nct_id":"NCT02530658","title":"Next Generation Sequencing of Normal Tissues Prospectively in Pediatric Oncology Patients","phase":"","overall_status":"RECRUITING","enrollment_count":2500,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":false},{"nct_id":"NCT04031638","title":"Thyroid Cancer Database","phase":"","overall_status":"UNKNOWN","enrollment_count":2300,"lead_sponsor_name":"Centre Georges Francois Leclerc","has_results":false},{"nct_id":"NCT06406829","title":"Perioperative Multimodal Analgesia Protocol for Supratentorial Craniotomy","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Beijing Tiantan Hospital","has_results":false},{"nct_id":"NCT07441421","title":"Perioperative Multimodal Analgesia for Supratentorial Craniotomy","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Beijing Tiantan Hospital","has_results":false},{"nct_id":"NCT04256525","title":"Prophylactic Anticoagulation for Catheter-related Thrombosis","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":1640,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT03474601","title":"Seoul National University Pituitary Disease Cohort Study","phase":"","overall_status":"UNKNOWN","enrollment_count":1600,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT06526897","title":"Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk Truncal-Extremity Soft Tissue Sarcoma","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":1582,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":false},{"nct_id":"NCT00951496","title":"Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1560,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06702566","title":"The Effect of Serum Ferritin in irAE","phase":"NA","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT04596865","title":"Recurrence After Whipple's (RAW) Study","phase":"","overall_status":"COMPLETED","enrollment_count":1484,"lead_sponsor_name":"University Hospital Plymouth NHS Trust","has_results":false},{"nct_id":"NCT03155620","title":"Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1377,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT00919750","title":"Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors","phase":"","overall_status":"COMPLETED","enrollment_count":1258,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT07167095","title":"90-Day Mortality After Emergency Department Discharge in Advanced Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":1250,"lead_sponsor_name":"Ankara Etlik City Hospital","has_results":false},{"nct_id":"NCT00108745","title":"Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":1157,"lead_sponsor_name":"GOG Foundation","has_results":true},{"nct_id":"NCT00477958","title":"Assessment Tool for Older Patients With Cancer","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1062,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT00565851","title":"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1052,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03398915","title":"The European Robotic Spinal Instrumentation (EUROSPIN) Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":932,"lead_sponsor_name":"Marc Schröder","has_results":true},{"nct_id":"NCT00899990","title":"Collecting and Storing Biological Samples From Patients With Ewing Sarcoma","phase":"","overall_status":"COMPLETED","enrollment_count":908,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT05601570","title":"Impact of the Experience of Anaesthetists in Changing Ventilation Strategies During Panendoscopy on the Incidence of Intraoperative Hypoxaemia","phase":"","overall_status":"UNKNOWN","enrollment_count":850,"lead_sponsor_name":"Centre Hospitalier Universitaire de Besancon","has_results":false},{"nct_id":"NCT02834013","title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":818,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06914700","title":"A Nomogram for Predicting the Diagnosis of Central Malignant Tumors Based on Preoperative Clinical Characteristics and Laboratory Indicators:","phase":"","overall_status":"COMPLETED","enrollment_count":800,"lead_sponsor_name":"Guangdong Provincial People's Hospital","has_results":false},{"nct_id":"NCT01231347","title":"QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":800,"lead_sponsor_name":"NantCell, Inc.","has_results":true},{"nct_id":"NCT05038254","title":"Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":750,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03475953","title":"A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":747,"lead_sponsor_name":"Institut Bergonié","has_results":false},{"nct_id":"NCT04283032","title":"Impact of Magnetic Resonance and Biomarkers for Screening for Prostate Cancer. Cost-effectiveness Analysis","phase":"","overall_status":"UNKNOWN","enrollment_count":628,"lead_sponsor_name":"InvestigatorUrologyIBSAL","has_results":false},{"nct_id":"NCT06251830","title":"Increasing Diagnosis Rates While Reducing Examination Time: Can MR Fingerprinting Deliver on Its Promise?","phase":"","overall_status":"COMPLETED","enrollment_count":610,"lead_sponsor_name":"IRCCS Fondazione Stella Maris","has_results":false},{"nct_id":"NCT04427384","title":"Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"GT Medical Technologies, Inc.","has_results":false},{"nct_id":"NCT03496402","title":"Biological Characterisation of High Risk CHildhood Cancer in Children, Adolescents and Young Adults (MICCHADO)","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":600,"lead_sponsor_name":"Institut Curie","has_results":false},{"nct_id":"NCT01365169","title":"Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients\"","phase":"NA","overall_status":"RECRUITING","enrollment_count":590,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02446600","title":"Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":579,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT00482677","title":"Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":562,"lead_sponsor_name":"Canadian Cancer Trials Group","has_results":true},{"nct_id":"NCT00978458","title":"Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":540,"lead_sponsor_name":"Eastern Cooperative Oncology Group","has_results":false},{"nct_id":"NCT06330064","title":"A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":520,"lead_sponsor_name":"Daiichi Sankyo","has_results":false},{"nct_id":"NCT07378683","title":"A Clinical Prediction Model for Surgical Site Infection After Central Nervous System Tumor Surgery","phase":"NA","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Ming Yang","has_results":false},{"nct_id":"NCT04852354","title":"Tissue Collection for Drug Screening and Bioanalysis","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Weill Medical College of Cornell University","has_results":false},{"nct_id":"NCT05895214","title":"Mesopancreas Study in Pancreatic Cancer","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":500,"lead_sponsor_name":"Heinrich-Heine University, Duesseldorf","has_results":false},{"nct_id":"NCT07243379","title":"A Prospective Real-World Observational Study of Nanocrystalline Megestrol Acetate in Patients With Cancer Cachexia","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":495,"lead_sponsor_name":"Changchun GeneScience Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT04526106","title":"REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":490,"lead_sponsor_name":"Elevar Therapeutics","has_results":false},{"nct_id":"NCT05593718","title":"Comparison of HFNO and FMV on Desaturations During Panendoscopy Under General Anesthesia","phase":"","overall_status":"UNKNOWN","enrollment_count":450,"lead_sponsor_name":"Centre Hospitalier Universitaire de Besancon","has_results":false},{"nct_id":"NCT00989651","title":"Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":431,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02052778","title":"A Study of TAS-120 in Patients With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":407,"lead_sponsor_name":"Taiho Oncology, Inc.","has_results":true},{"nct_id":"NCT02630654","title":"Study For Evaluating The Value Of A Multi Biomarker Approach In Metastatic GEP NETs","phase":"","overall_status":"COMPLETED","enrollment_count":404,"lead_sponsor_name":"Ipsen","has_results":false},{"nct_id":"NCT05672043","title":"Genetic and Molecular Risk Profiles of Pediatric Malignant Brain Tumors in China","phase":"","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Beijing Tiantan Hospital","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}